Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) Notes Receivable: ¥0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688621 Beijing Sun-Novo Pharmaceutical Research Co Ltd SHSE:688621
92 GF Score
Price ¥70.65
GF Value ¥65.02
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Beijing Sun-Novo Pharmaceutical Research Co Notes Receivable?

Beijing Sun-Novo Pharmaceutical Research Co SHSE:688621 +0.13% 92 Notes Receivable is ¥0 Mil as of Jun. 2026. GuruFocus rates SHSE:688621 with a GF Score™ of 92/100 and a GF Value™ of ¥65.02 (Fairly Valued). The stock has 9 warning signs investors should review.

Beijing Sun-Novo Pharmaceutical Research Co's Notes Receivable for the quarter that ended in Jun. 2026 was ¥0 Mil.

Beijing Sun-Novo Pharmaceutical Research Co Notes Receivable Related Terms

Beijing Sun-Novo Pharmaceutical Research Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Beijing Sun-Novo Pharmaceutical Research Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Sun-Novo Pharmaceutical Research Co Notes Receivable Chart

Beijing Sun-Novo Pharmaceutical Research Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Beijing Sun-Novo Pharmaceutical Research Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SHSE:688621
92GF Score
Beijing Sun-Novo Pharmaceutical Research Co Ltd SHSE:688621
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Sun-Novo Pharmaceutical Research Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ¥0 Mil mean?
Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) has a Notes Receivable of ¥0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Beijing Sun-Novo Pharmaceutical Research Co and its competitors.
Is Beijing Sun-Novo Pharmaceutical Research Co's Notes Receivable too high?
Beijing Sun-Novo Pharmaceutical Research Co's current Notes Receivable is ¥0 Mil. Overall, Beijing Sun-Novo Pharmaceutical Research Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Sun-Novo Pharmaceutical Research Co's Notes Receivable compare to ZTS?
Beijing Sun-Novo Pharmaceutical Research Co's Notes Receivable of ¥0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Beijing Sun-Novo Pharmaceutical Research Co and its competitors. Beijing Sun-Novo Pharmaceutical Research Co's current Notes Receivable is ¥0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Sun-Novo Pharmaceutical Research Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) is currently considered Fairly Valued. The stock's GF Value™ is ¥65.02, compared to a current price of ¥70.65 — trading 8.7% above its estimated fair value. The current Notes Receivable is ¥0 Mil. Beijing Sun-Novo Pharmaceutical Research Co's overall GF Score™ is 92/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621), the current Notes Receivable is ¥0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Sun-Novo Pharmaceutical Research Co stock appears to be overvalued. The current stock price of ¥70.65 is trading 8.7% above its estimated GF Value™ of ¥65.02. GuruFocus considers Beijing Sun-Novo Pharmaceutical Research Co to be Fairly Valued.

Key valuation signals for SHSE:688621:

  • Notes Receivable: ¥0 Mil
  • GF Value™: ¥65.02 vs. price of ¥70.65 (8.7% above fair value)
  • GF Score™: 92/100 with 9 warning signs

No single metric tells the full story. See the SHSE:688621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Sun-Novo Pharmaceutical Research Co Business Description

Address No. 79 Shuangying West Road, 1st Floor, Building 7, Science Park, Changping District, Beijing, CHN, 102200
Beijing Sun-Novo Pharmaceutical Research Co Ltd is engaged in providing professional research and development outsourcing services for pharmaceutical companies.
92GF Score

Get the complete analysis for SHSE:688621

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥70.65
Price
¥65.02
GF Value